首页 > 最新文献

Forum for Health Economics and Policy最新文献

英文 中文
Can Oral Nutritional Supplements Improve Medicare Patient Outcomes in the Hospital? 口服营养补充剂能改善医院医疗保险患者的预后吗?
Q3 Economics, Econometrics and Finance Pub Date : 2014-09-01 DOI: 10.1515/fhep-2014-0011
D. Lakdawalla, J. Snider, D. Perlroth, C. LaVallee, M. Linthicum, T. Philipson, J. Partridge, P. Wischmeyer
Abstract We analyzed the effect of oral nutritional supplement (ONS) use on 30-day readmission rates, length of stay (LOS), and episode costs in hospitalized Medicare patients (≥65), and subsets of patients diagnosed with acute myocardial infarction (AMI), congestive heart failure (CHF) or pneumonia (PNA). Propensity-score matching and instrumental variables were used to analyze ONS and non-ONS episodes from the Premier Research Database (2000–2010). ONS use was associated with reductions in probability of 30-day readmission by 12.0% in AMI and 10.1% in CHF. LOS decreases of 10.9% in AMI, 14.2% in CHF, and 8.5% in PNA were associated with ONS, as were decreases in episode costs in AMI, CHF and PNA of 5.1%, 7.8% and 10.6%, respectively. The effect on LOS and episode cost was greatest for the Any Diagnosis population, with decreases of 16.0% and 15.8%, respectively. ONS use in hospitalized Medicare patients ≥65 is associated with improved outcomes and decreased healthcare costs, and is therefore relevant to providers seeking an inexpensive, evidence-based approach for meeting Affordable Care Act quality targets.
我们分析了口服营养补充剂(ONS)使用对住院医保患者(≥65岁)30天再入院率、住院时间(LOS)和发作费用的影响,以及诊断为急性心肌梗死(AMI)、充血性心力衰竭(CHF)或肺炎(PNA)患者亚群的影响。倾向得分匹配和工具变量用于分析来自Premier Research Database(2000-2010)的国家统计局和非国家统计局事件。使用ONS与AMI患者30天再入院概率降低12.0%和CHF患者降低10.1%相关。AMI患者的LOS降低10.9%,CHF患者的LOS降低14.2%,PNA患者的LOS降低8.5%与ONS相关,AMI、CHF和PNA患者的发作成本分别降低5.1%、7.8%和10.6%。对任意诊断人群的LOS和发作费用的影响最大,分别下降了16.0%和15.8%。在65岁以上的住院医疗保险患者中使用ONS与改善预后和降低医疗成本相关,因此与寻求廉价、循证方法以满足《平价医疗法案》质量目标的提供者相关。
{"title":"Can Oral Nutritional Supplements Improve Medicare Patient Outcomes in the Hospital?","authors":"D. Lakdawalla, J. Snider, D. Perlroth, C. LaVallee, M. Linthicum, T. Philipson, J. Partridge, P. Wischmeyer","doi":"10.1515/fhep-2014-0011","DOIUrl":"https://doi.org/10.1515/fhep-2014-0011","url":null,"abstract":"Abstract We analyzed the effect of oral nutritional supplement (ONS) use on 30-day readmission rates, length of stay (LOS), and episode costs in hospitalized Medicare patients (≥65), and subsets of patients diagnosed with acute myocardial infarction (AMI), congestive heart failure (CHF) or pneumonia (PNA). Propensity-score matching and instrumental variables were used to analyze ONS and non-ONS episodes from the Premier Research Database (2000–2010). ONS use was associated with reductions in probability of 30-day readmission by 12.0% in AMI and 10.1% in CHF. LOS decreases of 10.9% in AMI, 14.2% in CHF, and 8.5% in PNA were associated with ONS, as were decreases in episode costs in AMI, CHF and PNA of 5.1%, 7.8% and 10.6%, respectively. The effect on LOS and episode cost was greatest for the Any Diagnosis population, with decreases of 16.0% and 15.8%, respectively. ONS use in hospitalized Medicare patients ≥65 is associated with improved outcomes and decreased healthcare costs, and is therefore relevant to providers seeking an inexpensive, evidence-based approach for meeting Affordable Care Act quality targets.","PeriodicalId":38039,"journal":{"name":"Forum for Health Economics and Policy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79479196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
The Effects of Smoking Cessation on Weight Gain: New Evidence Using Workplace Smoking Bans 戒烟对体重增加的影响:工作场所禁烟的新证据
Q3 Economics, Econometrics and Finance Pub Date : 2014-09-01 DOI: 10.1515/fhep-2013-0004
Jason M. Fletcher
Abstract Both tobacco use and obesity are among the most important and costly health challenges faced in developed countries. Unfortunately, they may be inversely linked. While policy interventions that have placed limits on tobacco use have increased substantially over time, one unintended consequence may be to increase obesity rates. Issues of selection and unobserved heterogeneity make it difficult to empirically assess the relationship between the two health outcomes. Additionally, there may be heterogeneous policy effects by cessation cause – smoking bans or medical treatments or tobacco prices. This paper focuses on the effects of a rapidly expanding policy by using within-individual differences in exposure to workplace smoking bans to estimate the impact of smoking cessation on weight gain using a large study of over 5000 White and Black respondents followed since 1986. Findings suggest that individuals affected by the smoking bans gained more weight in the short-term than suggested by OLS estimates.
烟草使用和肥胖都是发达国家面临的最重要和最昂贵的健康挑战。不幸的是,它们可能是反向关联的。虽然限制烟草使用的政策干预措施随着时间的推移大大增加,但一个意想不到的后果可能是肥胖率的增加。选择的问题和未观察到的异质性使得很难从经验上评估两种健康结果之间的关系。此外,戒烟禁令、医疗或烟草价格可能会产生不同的政策影响。本文通过对5000多名白人和黑人受访者自1986年以来进行的一项大型研究,利用工作场所禁烟令暴露的个体内部差异来估计戒烟对体重增加的影响,重点关注一项迅速扩大的政策的影响。研究结果表明,受禁烟令影响的个人在短期内的体重增加比OLS估计的要多。
{"title":"The Effects of Smoking Cessation on Weight Gain: New Evidence Using Workplace Smoking Bans","authors":"Jason M. Fletcher","doi":"10.1515/fhep-2013-0004","DOIUrl":"https://doi.org/10.1515/fhep-2013-0004","url":null,"abstract":"Abstract Both tobacco use and obesity are among the most important and costly health challenges faced in developed countries. Unfortunately, they may be inversely linked. While policy interventions that have placed limits on tobacco use have increased substantially over time, one unintended consequence may be to increase obesity rates. Issues of selection and unobserved heterogeneity make it difficult to empirically assess the relationship between the two health outcomes. Additionally, there may be heterogeneous policy effects by cessation cause – smoking bans or medical treatments or tobacco prices. This paper focuses on the effects of a rapidly expanding policy by using within-individual differences in exposure to workplace smoking bans to estimate the impact of smoking cessation on weight gain using a large study of over 5000 White and Black respondents followed since 1986. Findings suggest that individuals affected by the smoking bans gained more weight in the short-term than suggested by OLS estimates.","PeriodicalId":38039,"journal":{"name":"Forum for Health Economics and Policy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80018539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Patient Outcomes and Cost Effects of Medicaid Formulary Restrictions on Antidepressants 医疗补助限制抗抑郁药的患者结局和成本效应
Q3 Economics, Econometrics and Finance Pub Date : 2014-09-01 DOI: 10.1515/fhep-2014-0016
S. Seabury, D. Lakdawalla, D. Walter, J. Hayes, T. Gustafson, A. Shrestha, D. Goldman
Abstract Many state Medicaid programs have implemented policies designed to reduce spending on prescription drugs by restricting access to branded products. For patients with major depressive disorder, formulary restrictions could severely limit access to antidepressant therapies and disrupt care. We linked data on patient outcomes and spending from 24 state Medicaid programs to information on formulary restrictions from 2001 to 2008. Outcomes included frequency of MDD-related hospitalizations and ER visits per patient and total healthcare spending. We estimated the effect of the policies on patient outcomes and spending using a difference-and-difference approach. We found that restricting access to antidepressants increased the probability of an MDD-related hospitalization by 1.7 percentage points (16.6%). Furthermore, we found no evidence that these restrictions resulted in any net savings for Medicaid.
许多州的医疗补助计划已经实施了旨在通过限制获得品牌产品来减少处方药支出的政策。对于重度抑郁症患者,处方限制可能严重限制获得抗抑郁治疗并扰乱护理。我们将2001年至2008年24个州医疗补助计划的患者结果和支出数据与处方限制信息联系起来。结果包括与mdd相关的住院次数和每个患者的急诊次数以及总医疗支出。我们使用差异和差异方法估计了政策对患者结果和支出的影响。我们发现限制抗抑郁药的使用使mdd相关住院的概率增加了1.7个百分点(16.6%)。此外,我们没有发现任何证据表明这些限制导致了医疗补助的净节省。
{"title":"Patient Outcomes and Cost Effects of Medicaid Formulary Restrictions on Antidepressants","authors":"S. Seabury, D. Lakdawalla, D. Walter, J. Hayes, T. Gustafson, A. Shrestha, D. Goldman","doi":"10.1515/fhep-2014-0016","DOIUrl":"https://doi.org/10.1515/fhep-2014-0016","url":null,"abstract":"Abstract Many state Medicaid programs have implemented policies designed to reduce spending on prescription drugs by restricting access to branded products. For patients with major depressive disorder, formulary restrictions could severely limit access to antidepressant therapies and disrupt care. We linked data on patient outcomes and spending from 24 state Medicaid programs to information on formulary restrictions from 2001 to 2008. Outcomes included frequency of MDD-related hospitalizations and ER visits per patient and total healthcare spending. We estimated the effect of the policies on patient outcomes and spending using a difference-and-difference approach. We found that restricting access to antidepressants increased the probability of an MDD-related hospitalization by 1.7 percentage points (16.6%). Furthermore, we found no evidence that these restrictions resulted in any net savings for Medicaid.","PeriodicalId":38039,"journal":{"name":"Forum for Health Economics and Policy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89589914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
A Note on Income Effects and Health Care Cost Growth in Medicare 关于医疗保险的收入效应和医疗保健成本增长的说明
Q3 Economics, Econometrics and Finance Pub Date : 2014-02-01 DOI: 10.1515/fhep-2013-0001
T. Mcguire
Abstract This paper sets out a model of technical change and health care cost growth for a representative Medicare beneficiary facing a budget constraint. Derivation of an explicit expression for health care cost growth shows how technological change and preferences, including income effects, affect cost growth. The analysis highlights the role of the 76% subsidy from current taxpayers to Medicare beneficiaries for purchase of health insurance. This subsidy insulates beneficiaries from the income effects of cost growth by shifting the costs and income effects to taxpayers. Simulations show that over the next 10–20 years, income effects will have little effect on cost growth in Medicare.
摘要本文提出了一个具有代表性的医疗保险受益人面临预算约束的技术变革和医疗保健成本增长模型。对医疗保健成本增长的显式表达式的推导表明,技术变革和偏好,包括收入效应,如何影响成本增长。分析强调了当前纳税人向医疗保险受益人提供的76%的医疗保险补贴的作用。这种补贴通过将成本和收入效应转移到纳税人身上,使受益人免受成本增长的收入效应的影响。模拟显示,在未来10-20年,收入效应对医疗保险成本增长的影响微乎其微。
{"title":"A Note on Income Effects and Health Care Cost Growth in Medicare","authors":"T. Mcguire","doi":"10.1515/fhep-2013-0001","DOIUrl":"https://doi.org/10.1515/fhep-2013-0001","url":null,"abstract":"Abstract This paper sets out a model of technical change and health care cost growth for a representative Medicare beneficiary facing a budget constraint. Derivation of an explicit expression for health care cost growth shows how technological change and preferences, including income effects, affect cost growth. The analysis highlights the role of the 76% subsidy from current taxpayers to Medicare beneficiaries for purchase of health insurance. This subsidy insulates beneficiaries from the income effects of cost growth by shifting the costs and income effects to taxpayers. Simulations show that over the next 10–20 years, income effects will have little effect on cost growth in Medicare.","PeriodicalId":38039,"journal":{"name":"Forum for Health Economics and Policy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85873619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
A Note on Income Effects and Health Care Cost Growth in Medicare. 关于医疗保险的收入效应和医疗保健成本增长的说明。
Q3 Economics, Econometrics and Finance Pub Date : 2014-02-01 DOI: 10.1515/fhep-2013-0
Thomas G McGuire

This paper sets out a model of technical change and health care cost growth for a representative Medicare beneficiary facing a budget constraint. Derivation of an explicit expression for health care cost growth shows how technological change and preferences, including income effects, affect cost growth. The analysis highlights the role of the 76% percent subsidy from current taxpayers to Medicare beneficiaries for purchase of health insurance. This subsidy insulates beneficiaries from the income effects of cost growth by shifting the costs and income effects to taxpayers. Simulations show that over the next 10-20 years, income effects will have little effect on cost growth in Medicare.

本文为面临预算约束的代表性医疗保险受益人建立了一个技术变革和医疗保健成本增长的模型。对医疗保健成本增长的显式表达式的推导表明,技术变革和偏好,包括收入效应,如何影响成本增长。该分析强调了当前纳税人向医疗保险受益人提供的76%的购买健康保险补贴的作用。这种补贴通过将成本和收入效应转移到纳税人身上,使受益人免受成本增长的收入效应的影响。模拟显示,在未来10-20年,收入效应对医疗保险成本增长的影响微乎其微。
{"title":"A Note on Income Effects and Health Care Cost Growth in Medicare.","authors":"Thomas G McGuire","doi":"10.1515/fhep-2013-0","DOIUrl":"https://doi.org/10.1515/fhep-2013-0","url":null,"abstract":"<p><p>This paper sets out a model of technical change and health care cost growth for a representative Medicare beneficiary facing a budget constraint. Derivation of an explicit expression for health care cost growth shows how technological change and preferences, including income effects, affect cost growth. The analysis highlights the role of the 76% percent subsidy from current taxpayers to Medicare beneficiaries for purchase of health insurance. This subsidy insulates beneficiaries from the income effects of cost growth by shifting the costs and income effects to taxpayers. Simulations show that over the next 10-20 years, income effects will have little effect on cost growth in Medicare.</p>","PeriodicalId":38039,"journal":{"name":"Forum for Health Economics and Policy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548929/pdf/nihms-713000.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34026350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Crowd, the Cloud and Improving the Future of Medical Device Innovation 人群、云与改善医疗器械创新的未来
Q3 Economics, Econometrics and Finance Pub Date : 2014-01-01 DOI: 10.1515/fhep-2012-0023
Marco D. Huesch, R. Szczerba
Abstract Barriers and delays to medical device innovation are often solely attributable to the regulatory environment instead of both the current state of innovation practices and product development processes in the industry. Increasing the pace of innovation while reducing costs requires the creation of a new approach that fits both established medical device corporations as well as entrepreneurial start-ups. In this commentary we advance the concept of innovation platforms to facilitate ideation in the medical device space. Such platforms could also allow the full health benefits from individual medical devices to be reaped, by overcoming interoperability concerns through simulation and credentialing. Given the dramatic benefits of medical device success, such non-traditional business models for development may be potential solutions for industry, users and regulators.
医疗器械创新的障碍和延迟通常仅仅归因于监管环境,而不是行业中创新实践和产品开发过程的现状。要在降低成本的同时加快创新步伐,就需要创造一种既适合老牌医疗设备公司,也适合创业型初创企业的新方法。在这篇评论中,我们提出了创新平台的概念,以促进医疗器械领域的创新。这些平台还可以通过模拟和认证克服互操作性问题,从而实现个人医疗设备的全部健康效益。鉴于医疗设备成功带来的巨大好处,这种非传统的发展商业模式可能是行业、用户和监管机构的潜在解决方案。
{"title":"The Crowd, the Cloud and Improving the Future of Medical Device Innovation","authors":"Marco D. Huesch, R. Szczerba","doi":"10.1515/fhep-2012-0023","DOIUrl":"https://doi.org/10.1515/fhep-2012-0023","url":null,"abstract":"Abstract Barriers and delays to medical device innovation are often solely attributable to the regulatory environment instead of both the current state of innovation practices and product development processes in the industry. Increasing the pace of innovation while reducing costs requires the creation of a new approach that fits both established medical device corporations as well as entrepreneurial start-ups. In this commentary we advance the concept of innovation platforms to facilitate ideation in the medical device space. Such platforms could also allow the full health benefits from individual medical devices to be reaped, by overcoming interoperability concerns through simulation and credentialing. Given the dramatic benefits of medical device success, such non-traditional business models for development may be potential solutions for industry, users and regulators.","PeriodicalId":38039,"journal":{"name":"Forum for Health Economics and Policy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89012401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Medicare Reimbursement Reform for Provider Visits and Health Outcomes in Patients on Hemodialysis. 医疗保险报销改革对提供者访问和血液透析患者的健康结果。
Q3 Economics, Econometrics and Finance Pub Date : 2014-01-01 DOI: 10.1515/fhep-2012-0018
Kevin F Erickson, Wolfgang C Winkelmayer, Glenn M Chertow, Jay Bhattacharya

The relation between the quantity of many healthcare services delivered and health outcomes is uncertain. In January 2004, the Centers for Medicare and Medicaid Services introduced a tiered fee-for-service system for patients on hemodialysis, creating an incentive for providers to see patients more frequently. We analyzed the effect of this change on patient mortality, transplant wait-listing, and costs. While mortality rates for Medicare beneficiaries on hemodialysis declined after reimbursement reform, mortality declined more - or was no different - among patients whose providers were not affected by the economic incentive. Similarly, improved placement of patients on the kidney transplant waitlist was no different among patients whose providers were not affected by the economic incentive; payments for dialysis visits increased 13.7% in the year following reform. The payment system designed to increase provider visits to hemodialysis patients increased Medicare costs with no evidence of a benefit on survival or kidney transplant listing.

提供的许多保健服务的数量与健康结果之间的关系是不确定的。2004年1月,医疗保险和医疗补助服务中心为血液透析患者引入了分层收费服务体系,鼓励医疗服务提供者更频繁地为患者看病。我们分析了这一变化对患者死亡率、移植等待名单和费用的影响。虽然医疗保险受益人的血液透析死亡率在报销改革后下降了,但那些医疗服务提供者不受经济激励影响的患者死亡率下降得更多,或者没有什么不同。同样地,在供方不受经济激励影响的患者中,患者在肾移植等待名单上的位置改善没有什么不同;在改革后的一年里,透析就诊费用增加了13.7%。该支付系统旨在增加血透患者的就诊次数,增加了医疗保险费用,但没有证据表明对生存或肾移植有好处。
{"title":"Medicare Reimbursement Reform for Provider Visits and Health Outcomes in Patients on Hemodialysis.","authors":"Kevin F Erickson,&nbsp;Wolfgang C Winkelmayer,&nbsp;Glenn M Chertow,&nbsp;Jay Bhattacharya","doi":"10.1515/fhep-2012-0018","DOIUrl":"https://doi.org/10.1515/fhep-2012-0018","url":null,"abstract":"<p><p>The relation between the quantity of many healthcare services delivered and health outcomes is uncertain. In January 2004, the Centers for Medicare and Medicaid Services introduced a tiered fee-for-service system for patients on hemodialysis, creating an incentive for providers to see patients more frequently. We analyzed the effect of this change on patient mortality, transplant wait-listing, and costs. While mortality rates for Medicare beneficiaries on hemodialysis declined after reimbursement reform, mortality declined more - or was no different - among patients whose providers were not affected by the economic incentive. Similarly, improved placement of patients on the kidney transplant waitlist was no different among patients whose providers were not affected by the economic incentive; payments for dialysis visits increased 13.7% in the year following reform. The payment system designed to increase provider visits to hemodialysis patients increased Medicare costs with no evidence of a benefit on survival or kidney transplant listing.</p>","PeriodicalId":38039,"journal":{"name":"Forum for Health Economics and Policy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/fhep-2012-0018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34293533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
A Cost-Benefit Analysis of Using Evidence of Effectiveness in Terms of Progression Free Survival in Making Reimbursement Decisions on New Cancer Therapies 使用无进展生存期的有效性证据来制定新的癌症治疗报销决策的成本-收益分析
Q3 Economics, Econometrics and Finance Pub Date : 2014-01-01 DOI: 10.1515/fhep-2013-0025
Warren Stevens, T. Philipson, Yanyu Wu, Connie Chen, D. Lakdawalla
Abstract Payers increasingly require evidence of a statistically significant difference in overall survival (OS) for reimbursement of new cancer therapies. At the same time, it becomes increasingly costly to design clinical trials that measure OS endpoints instead of progression-free survival (PFS) endpoints. While PFS is often an imperfect proxy for OS effects, it is also faster and cheaper to measure accurately. This study develops a general cost-benefit framework that quantifies the competing trade-offs of the use of PFS versus that of OS in oncology reimbursement. We then apply this general framework to the illustrative case of metastatic renal cell carcinoma (mRCC). In the particular case of mRCC, the framework demonstrates that the net benefit to society from basing reimbursement decisions on PFS endpoints could be between $271 and $1271 million in the United States, or between €171 and €1128 million in Europe. In longevity terms, waiting for OS data in this case would result in a net loss of 3549–14,557 life-years among US patients, or 6785–27,993 life-years for European patients. While more stringent standards for medical evidence improve accuracy, they also impose countervailing costs on patients in terms of foregone health gains. These costs must be weighed against the benefits of greater accuracy. The magnitudes of the costs and benefits may vary across tumor types and need to be quantified systematically.
支付方越来越多地需要总生存期(OS)有统计学显著差异的证据来报销新的癌症疗法。与此同时,设计临床试验测量OS终点而不是无进展生存期(PFS)终点的成本越来越高。虽然PFS通常是OS效果的不完美代理,但准确测量它也更快、更便宜。本研究开发了一个一般的成本效益框架,量化了肿瘤报销中使用PFS与使用OS的竞争权衡。然后,我们将这一总体框架应用于转移性肾细胞癌(mRCC)的说明性病例。在mRCC的特殊情况下,该框架表明,基于PFS端点的报销决策对社会的净效益在美国可能在2.71亿至1.271亿美元之间,在欧洲可能在1.71亿至1.128亿欧元之间。就寿命而言,在这种情况下,等待OS数据将导致美国患者净损失3549-14,557生命年,或欧洲患者净损失6785-27,993生命年。虽然更严格的医学证据标准提高了准确性,但就放弃的健康收益而言,它们也给患者带来了相应的成本。这些代价必须与更高的准确性所带来的好处进行权衡。成本和收益的大小可能因肿瘤类型而异,需要系统地量化。
{"title":"A Cost-Benefit Analysis of Using Evidence of Effectiveness in Terms of Progression Free Survival in Making Reimbursement Decisions on New Cancer Therapies","authors":"Warren Stevens, T. Philipson, Yanyu Wu, Connie Chen, D. Lakdawalla","doi":"10.1515/fhep-2013-0025","DOIUrl":"https://doi.org/10.1515/fhep-2013-0025","url":null,"abstract":"Abstract Payers increasingly require evidence of a statistically significant difference in overall survival (OS) for reimbursement of new cancer therapies. At the same time, it becomes increasingly costly to design clinical trials that measure OS endpoints instead of progression-free survival (PFS) endpoints. While PFS is often an imperfect proxy for OS effects, it is also faster and cheaper to measure accurately. This study develops a general cost-benefit framework that quantifies the competing trade-offs of the use of PFS versus that of OS in oncology reimbursement. We then apply this general framework to the illustrative case of metastatic renal cell carcinoma (mRCC). In the particular case of mRCC, the framework demonstrates that the net benefit to society from basing reimbursement decisions on PFS endpoints could be between $271 and $1271 million in the United States, or between €171 and €1128 million in Europe. In longevity terms, waiting for OS data in this case would result in a net loss of 3549–14,557 life-years among US patients, or 6785–27,993 life-years for European patients. While more stringent standards for medical evidence improve accuracy, they also impose countervailing costs on patients in terms of foregone health gains. These costs must be weighed against the benefits of greater accuracy. The magnitudes of the costs and benefits may vary across tumor types and need to be quantified systematically.","PeriodicalId":38039,"journal":{"name":"Forum for Health Economics and Policy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75709695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Opportunities in the Economics of Personalized Health Care and Prevention 个性化卫生保健和预防经济学中的机遇
Q3 Economics, Econometrics and Finance Pub Date : 2013-09-01 DOI: 10.1515/fhep-2013-0012
D. Meltzer
Abstract Personalized medicine is best viewed from a broad perspective of trying to use information about a patient to improve care. While “personalized medicine” often emphasizes the value of genetic information, traditional clinical approaches to personalizing care based on patient phenotype, provider and system-level factors should not be neglected. As these diverse approaches to personalization are examined, tools such as cost-effectiveness analysis can provide important insights into the value of these approaches, strategies for their implementation and dissemination, and priorities for future research. Such analyses are likely to be most insightful if they recognize that patient and provider behaviors are essential determinants of the value of treatments and that patient factors in particular may have large effects on the value of treatments and the need for interventions to improve decision making. These comments suggest three major areas of opportunity for economic analyses of personalized medicine: (1) traditional clinical approaches to personalized medicine, (2) multi-perspective studies of the benefits and costs of personalized medicine, and (3) the role of behavior in the value of personalized medicine.
个性化医疗最好从一个广泛的角度来看待,即试图利用病人的信息来改善护理。虽然“个性化医疗”往往强调遗传信息的价值,但基于患者表型、提供者和系统层面因素的个性化护理的传统临床方法不应被忽视。随着对这些不同的个性化方法的研究,成本效益分析等工具可以为这些方法的价值、实施和传播策略以及未来研究的优先事项提供重要的见解。如果这些分析认识到患者和提供者的行为是治疗价值的基本决定因素,特别是患者因素可能对治疗价值和干预以改善决策的需要有很大影响,那么这些分析可能是最有见地的。这些评论提出了个性化医疗经济分析的三个主要机会领域:(1)个性化医疗的传统临床方法,(2)个性化医疗收益和成本的多视角研究,以及(3)行为在个性化医疗价值中的作用。
{"title":"Opportunities in the Economics of Personalized Health Care and Prevention","authors":"D. Meltzer","doi":"10.1515/fhep-2013-0012","DOIUrl":"https://doi.org/10.1515/fhep-2013-0012","url":null,"abstract":"Abstract Personalized medicine is best viewed from a broad perspective of trying to use information about a patient to improve care. While “personalized medicine” often emphasizes the value of genetic information, traditional clinical approaches to personalizing care based on patient phenotype, provider and system-level factors should not be neglected. As these diverse approaches to personalization are examined, tools such as cost-effectiveness analysis can provide important insights into the value of these approaches, strategies for their implementation and dissemination, and priorities for future research. Such analyses are likely to be most insightful if they recognize that patient and provider behaviors are essential determinants of the value of treatments and that patient factors in particular may have large effects on the value of treatments and the need for interventions to improve decision making. These comments suggest three major areas of opportunity for economic analyses of personalized medicine: (1) traditional clinical approaches to personalized medicine, (2) multi-perspective studies of the benefits and costs of personalized medicine, and (3) the role of behavior in the value of personalized medicine.","PeriodicalId":38039,"journal":{"name":"Forum for Health Economics and Policy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83254126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Value of Diagnostic Testing in Personalized Medicine 诊断测试在个体化医疗中的价值
Q3 Economics, Econometrics and Finance Pub Date : 2013-09-01 DOI: 10.1515/fhep-2013-0023
D. Goldman, Charu N. Gupta, E. Vasudeva, K. Trakas, R. Riley, D. Lakdawalla, D. Agus, N. Sood, A. Jena, T. Philipson
Abstract Personalized medicine – the targeting of therapies to individuals on the basis of their biological, clinical, or genetic characteristics – is thought to have the potential to transform health care. While much emphasis has been placed on the value of personalized therapies, less attention has been paid to the value generated by the diagnostic tests that direct patients to those targeted treatments. This paper presents a framework derived from information economics for assessing the value of diagnostics. We demonstrate, via a case study, that the social value of such diagnostics can be very large, both by avoiding unnecessary treatment and by identifying patients who otherwise would not get treated. Despite the potential social benefits, diagnostic development has been discouraged by cost-based, rather than value-based, reimbursement.
个性化医疗——根据个体的生物学、临床或遗传特征对其进行靶向治疗——被认为具有改变医疗保健的潜力。虽然很多人强调个性化治疗的价值,但很少有人关注引导患者接受这些针对性治疗的诊断测试所产生的价值。本文提出了一个源自信息经济学的框架,用于评估诊断的价值。我们通过一个案例研究证明,这种诊断的社会价值可以非常大,既可以避免不必要的治疗,也可以识别出本来不会得到治疗的患者。尽管有潜在的社会效益,但基于成本而不是基于价值的报销阻碍了诊断的发展。
{"title":"The Value of Diagnostic Testing in Personalized Medicine","authors":"D. Goldman, Charu N. Gupta, E. Vasudeva, K. Trakas, R. Riley, D. Lakdawalla, D. Agus, N. Sood, A. Jena, T. Philipson","doi":"10.1515/fhep-2013-0023","DOIUrl":"https://doi.org/10.1515/fhep-2013-0023","url":null,"abstract":"Abstract Personalized medicine – the targeting of therapies to individuals on the basis of their biological, clinical, or genetic characteristics – is thought to have the potential to transform health care. While much emphasis has been placed on the value of personalized therapies, less attention has been paid to the value generated by the diagnostic tests that direct patients to those targeted treatments. This paper presents a framework derived from information economics for assessing the value of diagnostics. We demonstrate, via a case study, that the social value of such diagnostics can be very large, both by avoiding unnecessary treatment and by identifying patients who otherwise would not get treated. Despite the potential social benefits, diagnostic development has been discouraged by cost-based, rather than value-based, reimbursement.","PeriodicalId":38039,"journal":{"name":"Forum for Health Economics and Policy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88608162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 21
期刊
Forum for Health Economics and Policy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1